Novartis shares drop after cholesterol drug study failure
Novartis shares fell 3.3% Monday morning after its cholesterol drug pelacarsen failed in a closely watched study, increasing pressure on its pipeline and casting new doubt on the approach.
Shares of Novartis BX:NOT fell 3.3% on Monday morning after its cholesterol drug failed in a closely watched study, casting fresh doubt on the therapeutic approach and raising the stakes for the Swiss drugmaker's upcoming data for a gene therapy.Late on Friday, Novartis said its drug pelacarsen did…